文献速递MDS 与骨髓增殖性肿瘤白血病

肥大细胞白血病:ECNM注册研究中患者的临床与分子特征及生存结局

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
PubMed 文献 · Blood Adv · 2023-01-01

该研究基于欧洲肥大细胞增多症能力网络(ECNM)注册库,评估了92例肥大细胞白血病(MCL)患者。中位总生存(OS)为1.6年;多因素分析显示MCL伴相关血液肿瘤(MCL-AHN)和异常核型与较差OS相关,而KIT D816V阳性和米哚妥林治疗与较好OS相关。

要点

  • MCL患者中34%为MCL-AHN,14%为慢性MCL,仅4.5%为白血病性MCL(循环肥大细胞≥10%)。
  • 62/85(73%)可评估患者检出KIT D816V,16/36(44%)接受二代测序者检出S/A/R突变。
  • 中位OS为1.6年;MCL-AHN(HR 4.7)和异常核型(HR 5.6)与较差OS相关,KIT D816V阳性(HR 0.33)和米哚妥林治疗(HR 0.32)与较好OS相关。

核心结论

  • 这些数据提供了迄今最全面的MCL临床病理、分子和治疗格局快照,应有助于进一步指导MCL的亚型划分和预后判断。

研究设计与样本

  • 评估了来自欧洲肥大细胞增多症能力网络(ECNM)注册库的92例MCL患者。

主要发现

  • 31例(34%)患者诊断为MCL伴相关血液肿瘤(MCL-AHN)。
  • 慢性MCL(无C类表现)占14%,仅4.5%为白血病性MCL(循环肥大细胞≥10%)。
  • 62/85(73%)可评估患者检出KIT D816V;9例(11%)检出其他KIT突变,14例(17%)未检出KIT变异。
  • 10例(17%)可评估患者核型异常;16/36(44%)接受二代测序的患者检出S/A/R突变。
  • 中位总生存(OS)为1.6年。

关键数值与推荐

  • 多因素分析(因事件率低排除S/A/R突变):MCL-AHN诊断与较差OS相关(HR 4.7;95%CI 1.7-13.0;P=0.001)。
  • 多因素分析:异常核型与较差OS相关(HR 5.6;95%CI 1.4-13.3;P=0.02)。
  • 多因素分析:KIT D816V阳性与较好OS相关(HR 0.33;95%CI 0.11-0.98;P=0.04)。
  • 多因素分析:米哚妥林治疗与较好OS相关(HR 0.32;95%CI 0.08-0.72;P=0.008)。
  • 米哚妥林是最常见治疗,65%患者接受,45%作为一线治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the European Competence Network on Mastocytosis registry. Thirty-one (34%) patients had a diagnosis of MCL with an associated hematologic neoplasm (MCL-AHN). Chronic MCL (lack of C-findings) comprised 14% of patients, and only 4.5% had "leukemic MCL" (≥10% circulating MCs). KIT D816V was found in 62/85 (73%) evaluable patients; 9 (11%) individuals exhibited alternative KIT mutations, and no KIT variants were detected in 14 (17%) subjects. Ten evaluable patients (17%) had an abnormal karyotype and the poor-risk SRSF2, ASXL1, and RUNX1 (S/A/R) mutations were identified in 16/36 (44%) patients who underwent next-generation sequencing. Midostaurin was the most common therapy administered to 65% of patients and 45% as first-line therapy. The median overall survival (OS) was 1.6 years. In multivariate analysis (S/A/R mutations excluded owing to low event rates), a diagnosis of MCL-AHN (hazard ratio [HR], 4.7; 95% confidence interval [CI], 1.7-13.0; P = .001) and abnormal karyotype (HR, 5.6; 95% CI, 1.4-13.3; P = .02) were associated with inferior OS; KIT D816V positivity (HR, 0.33; 95% CI, 0.11-0.98; P = .04) and midostaurin treatment (HR, 0.32; 95% CI, 0.08-0.72; P = .008) were associated with superior OS. These data provide the most comprehensive snapshot of the clinicopathologic, molecular, and treatment landscape of MCL to date, and should help further inform subtyping and prognostication of MCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kennedy VE, Perkins C, Reiter A, et al. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry. Blood Adv. 2023. PMID: 36094848. doi:10.1182/bloodadvances.2022008292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。